| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10914558 | Molecular Oncology | 2016 | 8 Pages |
Abstract
This study suggests IGF1R as a potential biomarker of improved clinical outcome in HR+ve BC patients treated with exemestane. Adding metformin to exemestane treatment may add to this effect.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Charla C. Engels, Nienke A. de Glas, Anita Sajet, Esther Bastiaannet, Vincent T.H.B.M. Smit, Peter J.K. Kuppen, Caroline Seynaeve, Cornelis J.H. van de Velde, Gerrit Jan Liefers,